COVID-19 Impact on Recombinant Protein Drugs Market , Global Research Reports 2020-2021

1.2 Market Segmentation

1.3 Research Objectives

1.4 Research Methodology

1.4.1 Research Process

1.4.2 Data Triangulation

1.4.3 Research Approach

1.4.4 Base Year

1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth

1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections

1.5.2 Covid-19 Impact: Commodity Prices Indices

1.5.3 Covid-19 Impact: Global Major Government Policy

1.6 The Covid-19 Impact on Recombinant Protein Drugs Industry

1.7 COVID-19 Impact: Recombinant Protein Drugs Market Trends

2 Global Recombinant Protein Drugs Quarterly Market Size Analysis

2.1 Recombinant Protein Drugs Business Impact Assessment - COVID-19

2.1.1 Global Recombinant Protein Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026

2.1.2 Global Recombinant Protein Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026

2.2 Global Recombinant Protein Drugs Quarterly Market Size 2020-2021

2.3 COVID-19-Driven Market Dynamics and Factor Analysis

2.3.1 Drivers

2.3.2 Restraints

2.3.3 Opportunities

2.3.4 Challenges

3 Quarterly Competitive Assessment, 2020

3.1 Global Recombinant Protein Drugs Quarterly Market Size by Manufacturers, 2019 VS 2020

3.2 Global Recombinant Protein Drugs Factory Price by Manufacturers

3.3 Location of Key Manufacturers Recombinant Protein Drugs Manufacturing Factories and Area Served

3.4 Date of Key Manufacturers Enter into Recombinant Protein Drugs Market

3.5 Key Manufacturers Recombinant Protein Drugs Product Offered

3.6 Mergers & Acquisitions, Expansion Plans

4 Impact of Covid-19 on Recombinant Protein Drugs Segments, By Type

4.1 Introduction

1.4.1 Recombinant DNA

1.4.2 Recombinant RNA

4.2 By Type, Global Recombinant Protein Drugs Market Size, 2019-2021

4.2.1 By Type, Global Recombinant Protein Drugs Market Size by Type, 2020-2021

4.2.2 By Type, Global Recombinant Protein Drugs Price, 2020-2021

5 Impact of Covid-19 on Recombinant Protein Drugs Segments, By Application

5.1 Overview

5.5.1 Pharmaceutical Industry

5.5.2 Other

5.2 By Application, Global Recombinant Protein Drugs Market Size, 2019-2021

5.2.1 By Application, Global Recombinant Protein Drugs Market Size by Application, 2019-2021

5.2.2 By Application, Global Recombinant Protein Drugs Price, 2020-2021

6 Geographic Analysis

6.1 Introduction

6.2 North America

6.2.1 Macroeconomic Indicators of US

6.2.2 US

6.2.3 Canada

6.3 Europe

6.3.1 Macroeconomic Indicators of Europe

6.3.2 Germany

6.3.3 France

6.3.4 UK

6.3.5 Italy

6.4 Asia-Pacific

6.4.1 Macroeconomic Indicators of Asia-Pacific

6.4.2 China

6.4.3 Japan

6.4.4 South Korea

6.4.5 India

6.4.6 ASEAN

6.5 Rest of World

6.5.1 Latin America

6.5.2 Middle East and Africa

7 Company Profiles

7.1 Novo Nordisk

7.1.1 Novo Nordisk Business Overview

7.1.2 Novo Nordisk Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.1.3 Novo Nordisk Recombinant Protein Drugs Product Introduction

7.1.4 Novo Nordisk Response to COVID-19 and Related Developments

7.2 Amgen

7.2.1 Amgen Business Overview

7.2.2 Amgen Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.2.3 Amgen Recombinant Protein Drugs Product Introduction

7.2.4 Amgen Response to COVID-19 and Related Developments

7.3 Sanofi

7.3.1 Sanofi Business Overview

7.3.2 Sanofi Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.3.3 Sanofi Recombinant Protein Drugs Product Introduction

7.3.4 Sanofi Response to COVID-19 and Related Developments

7.4 Eli Lilly

7.4.1 Eli Lilly Business Overview

7.4.2 Eli Lilly Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.4.3 Eli Lilly Recombinant Protein Drugs Product Introduction

7.4.4 Eli Lilly Response to COVID-19 and Related Developments

7.5 Merck Serono

7.5.1 Merck Serono Business Overview

7.5.2 Merck Serono Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.5.3 Merck Serono Recombinant Protein Drugs Product Introduction

7.5.4 Merck Serono Response to COVID-19 and Related Developments

7.6 Ortho Biotech

7.6.1 Ortho Biotech Business Overview

7.6.2 Ortho Biotech Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.6.3 Ortho Biotech Recombinant Protein Drugs Product Introduction

7.6.4 Ortho Biotech Response to COVID-19 and Related Developments

7.7 Roche

7.7.1 Roche Business Overview

7.7.2 Roche Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.7.3 Roche Recombinant Protein Drugs Product Introduction

7.7.4 Roche Response to COVID-19 and Related Developments

7.8 Kyowa Hakko Kirin

7.8.1 Kyowa Hakko Kirin Business Overview

7.8.2 Kyowa Hakko Kirin Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.8.3 Kyowa Hakko Kirin Recombinant Protein Drugs Product Introduction

7.8.4 Kyowa Hakko Kirin Response to COVID-19 and Related Developments

7.9 Pharmingen

7.9.1 Pharmingen Business Overview

7.9.2 Pharmingen Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.9.3 Pharmingen Recombinant Protein Drugs Product Introduction

7.9.4 Pharmingen Response to COVID-19 and Related Developments

7.10 Abcam

7.10.1 Abcam Business Overview

7.10.2 Abcam Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.10.3 Abcam Recombinant Protein Drugs Product Introduction

7.10.4 Abcam Response to COVID-19 and Related Developments

7.11 GenSci

7.11.1 GenSci Business Overview

7.11.2 GenSci Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.11.3 GenSci Recombinant Protein Drugs Product Introduction

7.11.4 GenSci Response to COVID-19 and Related Developments

7.12 SL PHARM

7.12.1 SL PHARM Business Overview

7.12.2 SL PHARM Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.12.3 SL PHARM Recombinant Protein Drugs Product Introduction

7.12.4 SL PHARM Response to COVID-19 and Related Developments

7.13 Dongbao Pharm

7.13.1 Dongbao Pharm Business Overview

7.13.2 Dongbao Pharm Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.13.3 Dongbao Pharm Recombinant Protein Drugs Product Introduction

7.13.4 Dongbao Pharm Response to COVID-19 and Related Developments

7.14 Ankebio

7.14.1 Ankebio Business Overview

7.14.2 Ankebio Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.14.3 Ankebio Recombinant Protein Drugs Product Introduction

7.14.4 Ankebio Response to COVID-19 and Related Developments

7.15 NCPC

7.15.1 NCPC Business Overview

7.15.2 NCPC Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.15.3 NCPC Recombinant Protein Drugs Product Introduction

7.15.4 NCPC Response to COVID-19 and Related Developments

7.16 Heng Rui

7.16.1 Heng Rui Business Overview

7.16.2 Heng Rui Recombinant Protein Drugs Quarterly Production and Revenue, 2020

7.16.3 Heng Rui Recombinant Protein Drugs Product Introduction

7.16.4 Heng Rui Response to COVID-19 and Related Developments

8 Supply Chain and Sales Channels Analysis

8.1 Recombinant Protein Drugs Supply Chain Analysis

8.1.1 Recombinant Protein Drugs Supply Chain Analysis

8.1.2 Covid-19 Impact on Recombinant Protein Drugs Supply Chain

8.2 Distribution Channels Analysis

8.2.1 Recombinant Protein Drugs Distribution Channels

8.2.2 Covid-19 Impact on Recombinant Protein Drugs Distribution Channels

8.2.3 Recombinant Protein Drugs Distributors

8.3 Recombinant Protein Drugs Customers

9 Key Findings

10 Appendix

10.1 About Us

10.2 Disclaimer

Table 1. Overview of the World Economic Outlook Projections

Table 2. Summary of World Real per Capita Output (Annual percent change; in international currency at purchasing power parity)

Table 3. European Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 4. Asian and Pacific Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 5. Western Hemisphere Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 6. Middle Eastern and Central Asian Economies: Real GDP, Consumer Prices, Current Account Balance, and Unemployment (Annual percent change, unless noted otherwise)

Table 7. Covid-19 Impact: Global Major Government Policy

Table 8. The Covid-19 Impact on Recombinant Protein Drugs Assessment

Table 9. COVID-19 Impact: Recombinant Protein Drugs Market Trends

Table 10. COVID-19 Impact Global Recombinant Protein Drugs Market Size

Table 11. Global Recombinant Protein Drugs Market Size Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (K Doses)

Table 12. Global Recombinant Protein Drugs Price, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026, (USD/Dose)

Table 13. Global Recombinant Protein Drugs Quarterly Market Size, 2020 (US$ Million) & (K Doses)

Table 14. Global Recombinant Protein Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (US$ Million)

Table 15. Global Recombinant Protein Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Quarterly Comparison, 2020-2021 (K Doses)

Table 16. Global Recombinant Protein Drugs Market Growth Drivers

Table 17. Global Recombinant Protein Drugs Market Restraints

Table 18. Global Recombinant Protein Drugs Market Opportunities

Table 19. Global Recombinant Protein Drugs Market Challenges

Table 20. Key Manufacturers Recombinant Protein Drugs Quarterly Revenue, 2019 VS 2020 (US$ Million)

Table 21. Top Manufacturers, Recombinant Protein Drugs Market Size, 2019 (K Doses) & (US$ Million)

Table 22. Recombinant Protein Drugs Factory Price by Manufacturers 2020 (USD/Dose)

Table 23. Location of Key Manufacturers Recombinant Protein Drugs Manufacturing Plants

Table 24. Key Manufacturers Recombinant Protein Drugs Market Served

Table 25. Date of Key Manufacturers Enter into Recombinant Protein Drugs Market

Table 26. Key Manufacturers Recombinant Protein Drugs Product Type

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Recombinant Protein Drugs Market Size by Type, 2020, (US$ Million)

Table 29. Global Recombinant Protein Drugs Market Size by Type, 2020 (K Doses)

Table 30. Global Recombinant Protein Drugs Price: by Type, 2020-2021 (USD/Dose)

Table 31. Global Recombinant Protein Drugs Market Size by Application: 2020-2021 (US$ Million)

Table 32. Global Recombinant Protein Drugs Market Size by Application, 2020-2021 (K Doses)

Table 33. Global Recombinant Protein Drugs Price: by Application, 2020-2021 (USD/Dose)

Table 34. Global Recombinant Protein Drugs Market Size by Region, 2019-2021 (US$ Million)

Table 35. Global Recombinant Protein Drugs Market Size by Region, 2019-2021 (K Doses)

Table 36. By Country, North America Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million)

Table 37. By Country, North America Recombinant Protein Drugs Market Size, 2019-2021 (K Doses)

Table 38. US Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 39. Canada Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 40. Macroeconomic Indicators of Europe (Germany, France, UK and Italy)

Table 41. By Country, Europe Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million)

Table 42. By Country, Europe Recombinant Protein Drugs Market Size, 2019-2021 (K Doses)

Table 43. Germany Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 44. France Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 45. UK Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 46. Italy Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 47. Macroeconomic Indicators of Asia-Pacific (China, Japan, South Korea, India and ASEAN)

Table 48. By Region, Asia-Pacific Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million)

Table 49. By Region, Asia-Pacific Recombinant Protein Drugs Market Size, 2019-2021 (K Doses)

Table 50. China Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 51. Japan Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 52. South Korea Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 53. India Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 54. ASEAN Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 55. Latin America Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 56. Middle East and Africa Recombinant Protein Drugs Market Size, 2019-2021 (US$ Million) & (K Doses)

Table 57. Novo Nordisk Business Overview

Table 58. Novo Nordisk Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 59. Novo Nordisk Recombinant Protein Drugs Product

Table 60. Novo Nordisk Response to COVID-19 and Related Developments

Table 61. Amgen Business Overview

Table 62. Amgen Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 63. Amgen Recombinant Protein Drugs Product

Table 64. Amgen Response to COVID-19 and Related Developments

Table 65. Sanofi Business Overview

Table 66. Sanofi Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 67. Sanofi Recombinant Protein Drugs Product

Table 68. Sanofi Response to COVID-19 and Related Developments

Table 69. Eli Lilly Business Overview

Table 70. Eli Lilly Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 71. Eli Lilly Recombinant Protein Drugs Product

Table 72. Eli Lilly Response to COVID-19 and Related Developments

Table 73. Merck Serono Business Overview

Table 74. Merck Serono Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 75. Merck Serono Recombinant Protein Drugs Product

Table 76. Merck Serono Response to COVID-19 and Related Developments

Table 77. Ortho Biotech Business Overview

Table 78. Ortho Biotech Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 79. Ortho Biotech Recombinant Protein Drugs Product

Table 80. Ortho Biotech Response to COVID-19 and Related Developments

Table 81. Roche Business Overview

Table 82. Roche Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 83. Roche Recombinant Protein Drugs Product

Table 84. Roche Response to COVID-19 and Related Developments

Table 85. Kyowa Hakko Kirin Business Overview

Table 86. Kyowa Hakko Kirin Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 87. Kyowa Hakko Kirin Recombinant Protein Drugs Product

Table 88. Kyowa Hakko Kirin Response to COVID-19 and Related Developments

Table 89. Pharmingen Business Overview

Table 90. Pharmingen Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 91. Pharmingen Recombinant Protein Drugs Product

Table 92. Pharmingen Response to COVID-19 and Related Developments

Table 93. Abcam Business Overview

Table 94. Abcam Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 95. Abcam Recombinant Protein Drugs Product

Table 96. Abcam Response to COVID-19 and Related Developments

Table 97. GenSci Business Overview

Table 98. GenSci Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 99. GenSci Recombinant Protein Drugs Product

Table 100. GenSci Response to COVID-19 and Related Developments

Table 101. SL PHARM Business Overview

Table 102. SL PHARM Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 103. SL PHARM Recombinant Protein Drugs Product

Table 104. SL PHARM Response to COVID-19 and Related Developments

Table 105. Dongbao Pharm Business Overview

Table 106. Dongbao Pharm Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 107. Dongbao Pharm Recombinant Protein Drugs Product

Table 108. Dongbao Pharm Response to COVID-19 and Related Developments

Table 109. Ankebio Business Overview

Table 110. Ankebio Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 111. Ankebio Recombinant Protein Drugs Product

Table 112. Ankebio Response to COVID-19 and Related Developments

Table 113. NCPC Business Overview

Table 114. NCPC Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 115. NCPC Recombinant Protein Drugs Product

Table 116. NCPC Response to COVID-19 and Related Developments

Table 117. Heng Rui Business Overview

Table 118. Heng Rui Recombinant Protein Drugs Production (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin, (Q1, Q2, Q3, Q4) Quarter 2020

Table 119. Heng Rui Recombinant Protein Drugs Product

Table 120. Heng Rui Response to COVID-19 and Related Developments

Table 121. Recombinant Protein Drugs Distributors List

Table 122. Recombinant Protein Drugs Customers List

Table 123. Covid-19 Impact on Recombinant Protein Drugs Customers

List of Figures

Figure 1. Recombinant Protein Drugs Product Picture

Figure 2. Recombinant Protein Drugs Market Segmentation

Figure 3. Research Objectives

Figure 4. Research Process

Figure 5. Data Triangulation

Figure 6. Research Approach

Figure 7. Commodity Prices-Metals Price Indices

Figure 8. Commodity Prices- Precious Metal Price Indices

Figure 9. Commodity Prices- Agricultural Raw Material Price Indices

Figure 10. Commodity Prices- Food and Beverage Price Indices

Figure 11. Commodity Prices- Fertilizer Price Indices

Figure 12. Commodity Prices- Energy Price Indices

Figure 13. G20+: Economic Policy Responses to COVID-19

Figure 14. Global Recombinant Protein Drugs Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-2026 (US$ Million)

Figure 15. Global Recombinant Protein Drugs Market Size, Pre-COVID-19 and Post- COVID-19, Year-over-Year Growth Rate, 2015-2026 (%)

Figure 16. Global Recombinant Protein Drugs Market Size, Quarterly Growth, 2020-2021 (%)

Figure 17. Global Recombinant Protein Drugs Market Size, Market Share by Type, 2019 VS 2020 (%)

Figure 18. Global Recombinant Protein Drugs Market Size, Market Share by Application, 2019 VS 2020 (%)

Figure 19. Global Recombinant Protein Drugs Market Size Market Share by Region, 2019 VS 2020 (%)

Figure 20. United States Composite PMI and GDP

Figure 21. Eurozone Composite PMI and GDP

Figure 22. Eurozone Core v. Periphery PMI Output Indices

Figure 23. Core v. Periphery PMI Employment Indices

Figure 24. UK Composite PMI and GDP

Figure 25. Caixin China Composite Output Index

Figure 26. Caixin China General Services Business Activity Index

Figure 27. Japan Composite Output Index

Figure 28. South Korea Manufacturing PMI

Figure 29. India Composite Output Index

Figure 30. ASEAN Manufacturing PMI

Figure 31. By Region, Asia-Pacific Recombinant Protein Drugs Market Size Market Share, 2019-2021